|
|||||
|
|
Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB) |
|
| Authors: | Aminah Jatoi Shaker R. Dakhil Jeff A. Sloan John W. Kugler Kendrith M. Rowland Jr. Paul L. Schaefer Paul J. Novotny Donald B. Wender Howard M. Gross Charles L. Loprinzi |
| Affiliation: | (1) Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA;(2) Mayo Foundation, Rochester, MN 55905, USA;(3) Wichita Community Clinical Oncology Program, Wichita, KS 67214-3882, USA;(4) Illinois Oncology Research Association CCOP, Peoria, IL 61615-7828, USA;(5) Carle Cancer Center CCOP, Urbana, IL 61801, USA;(6) Toledo Community Hospital Oncology Program CCOP, Toledo, OH 43623, USA;(7) Siouxland Hematology–Oncology Associates, Sioux City, IA 51105, USA;(8) Michigan Cancer Research Consortium, Ann Arbor, MI 48106, USA |
| Abstract: | PurposePrevious studies suggest tetracycline and other antibiotics lessen the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash. This study sought to confirm such findings. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |